Osteoarthritis (OA) is a degenerative condition primarily characterized by the progressive deterioration of articular cartilage. Its pathogenesis is complex, and current treatment options remain limited……

（尊敬的各位专家、同仁：

首先允许我介绍一下我自己。

我是来自中国京州医院的吕慕轩。

我非常荣幸能在本次世界骨科大会上代表我们课题组汇报我们的研究

《帕提松与杉醇碱对DMM模型小鼠骨关节炎的疗效对比及机制研究》。

今天我将从研究背景、方法、结果与机制探讨四个方面展开介绍。

一、研究背景与目的

骨关节炎是一种以关节软骨退行性病变为核心的疾病，其发病机制复杂，治疗手段有限……）

吕慕轩没有看演讲稿，目光从容地扫过会场的每个角落，像是在与每一位听众进行单独的对话。

那份源于内心的自信，如同无形的气场，瞬间笼罩了整个空间。

汇报完毕，到了提问环节。

台下一位精神矍铄的外国老者，拿起了话筒，提问道：

"Dr. Lü, thank you for this fascinating presentation.

"I'm curious about the rationale behind your dose selection for Patisong and Taxine.

"Could you elaborate on how you determined the specific medium and high doses used in your study.

"and whether you encountered any surprises in the dose-response relationship？"

（吕博士，感谢您的精彩报告。

我对帕提松和杉醇碱的剂量选择依据很感兴趣。

能否请您详细说明研究中中、高具体剂量是如何确定的？

以及在量效关系方面是否观察到令人意外的现象？）

吕慕轩听到这个问题后思索了片刻，然后答道：“Thank you for that excellent question！

"Designing the doses was like preparing a multi-course meal—

you want enough variety to satisfy different appetites, but not so much that everyone leaves confused”

（感谢您的提问！

设计药物剂量就像准备一场宴会——既要菜品丰富满足不同口味，又不能过于复杂让客人无所适从。）

说到这里他自己不好意思地笑了：“Please forgive the analogy I used——

“it may not be the most appropriate, but it is the most fitting one I can think of at the moment.”

（请原谅我用了这样一个比喻，它也许不恰当，确实我现在能想到的最贴切的。）

台下不少人也跟着露出了笑容，会场上的气氛一时轻松起来。

吕慕轩接着回答道：“Our primary rationale was to capture a potential dose-response relationship while ensuring the doses were clinically relevant and safe for the animals. To achieve this, we did not rely on a single dose. Instead, for each drug, we established multiple dose groups. The selection of specific dosage levels was informed by prior safety data and preliminary studies. We aimed for a range that was wide enough to be meaningful: the low-dose group was set to identify a potential minimum effective dose, while the high-dose group was designed to approach, but not exceed, the maximum tolerated dose to maximize the chance of observing a therapeutic effect.”

This multi-dose approach allows us to determine not just if the drug works, but how its efficacy changes with dosage. It helps us understand the therapeutic window and provides a more robust dataset for evaluating the drug's true potential. Additionally, the inclusion of a standard positive control group provided a benchmark for efficacy, allowing us to contextualize the effects of our investigational drugs against a known therapy.

In summary, our dosing strategy was structured to be comprehensive, aiming to generate data that is both statistically sound and rich in information regarding the pharmacological profile of Patisong and Taxine."

（我们的主要理由是捕捉潜在的剂量反应关系，同时确保剂量对动物来说具有临床相关性且安全。为实现这一目标，我们并未依赖单一剂量。相反，对于每种药物，我们都设立了多个剂量组。具体剂量水平的选择参考了先前的安全数据和初步研究。我们力求剂量范围足够宽泛以具有实际意义：低剂量组旨在确定潜在的最小有效剂量，而高剂量组则旨在接近但不超过最大耐受剂量，以最大限度地提高观察到治疗效果的可能性……）

随着吕慕轩在台上侃侃而谈，台下的各位学者不时点头赞许。

最后，主持人说：“感谢吕先生的精彩汇报，我们有请下一位。”

吕慕轩微笑着下台走向座位，看着阳光对他鼓掌眼中满是赞许，他如释重负地笑了。